TOI · Insider Trading
The Oncology Institute, Inc. Common Stock
Every open-market purchase and sale reported by TOI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | Brad Hively | Director | Sell | −298,853 | −$1.95M |
| 2026-08-17 | Jorey Chernett | 10%+ Owner | Buy | +12,000 | +$78.48K |
| 2026-07-29 | Mark Stolper | Director | A | +31,124 | — |
| 2026-07-29 | Brad Hively | Director | A | +27,108 | — |
| 2026-07-29 | Mohit Kaushal | Director | A | +33,133 | — |
| 2026-07-29 | Kimberly Jo Tzoumakas | Director | A | +29,116 | — |
| 2026-07-29 | Mark L Pacala | Director | A | +30,120 | — |
| 2026-07-29 | Anne McGeorge | Director | A | +41,165 | — |
| 2026-07-29 | Karen Marie Johnson | Director | A | +31,124 | — |
| 2026-07-22 | Jorey Chernett | 10%+ Owner | Buy | +18,000 | +$94.86K |
| 2026-07-16 | Yale Podnos | Chief Medical Officer | MIXED | — | −$105.77K |
| 2026-07-13 | Jorey Chernett | 10%+ Owner | Buy | +15,000 | +$87.75K |
| 2026-07-09 | Mark Stolper | Director | A | +25,833 | — |
| 2026-07-09 | Kimberly Jo Tzoumakas | Director | A | +17,185 | — |
| 2026-06-24 | Jorey Chernett | 10%+ Owner | Buy | +18,000 | +$90.36K |
| 2022-08-23 | TOI HC I, LLC | 10%+ Owner | Sell | −94,473 | −$620.43K |
| 2022-08-16 | Havencrest Healthcare Partners GP, LLC | 10%+ Owner | Sell | −50,000 | −$324.39K |
| 2022-06-14 | Jimmy Holdings, Inc. | 10%+ Owner | Sell | −300,000 deriv. | — |
| 2022-05-19 | Mihir Shah | Chief Financial Officer | A | +32,121 | — |
| 2022-05-13 | Jimmy Holdings, Inc. | 10%+ Owner | Sell | −1,600,000 | −$9.60M |
| 2022-03-29 | Scott Dalgleish | Chief Financial Officer | A | +162,891 deriv. | — |
| 2022-03-29 | Daniel Virnich | President | A | +213,259 deriv. | — |
| 2022-03-29 | Brad Hively | Chief Executive Officer | A | +550,563 deriv. | — |
| 2022-03-29 | Matthew P Miller | Chief Operating Officer | A | +142,261 deriv. | — |
| 2022-03-29 | Yale Podnos | Chief Medical Officer | A | +75,551 deriv. | — |
| 2022-03-23 | Richard A Barasch | Director | A | +45,905 | — |
| 2022-03-23 | Scott Dalgleish | Chief Financial Officer | A | +32,092 | — |
| 2022-03-23 | Karen Marie Johnson | Director | A | +20,792 | — |
| 2022-03-23 | Mohit Kaushal | Director | A | +20,792 | — |
| 2022-03-23 | Brad Hively | Chief Executive Officer | A | +108,469 | — |
| 2022-03-23 | Daniel Virnich | President | A | +42,015 | — |
| 2022-03-23 | Ravi Yang Sarin | Director | A | +23,191 | — |
| 2022-03-23 | Anne McGeorge | Director | A | +22,391 | — |
| 2022-03-23 | Matthew P Miller | Chief Operating Officer | A | +28,027 | — |
| 2022-03-23 | Yale Podnos | Chief Medical Officer | A | +14,884 | — |
| 2022-03-23 | Maeve O'Meara | Director | A | +19,992 | — |
| 2021-11-24 | Richard A Barasch | Director | Buy | +5,000 | +$31.70K |
| 2021-11-24 | Richard A Barasch | Director | Buy | +5,000 | +$34.60K |
| 2021-11-22 | Ravi Yang Sarin | Director | A | +4,109,771 | — |
| 2021-11-18 | Mohit Kaushal | Director | M | +30,000 | — |
| 2021-11-18 | Richard A Barasch | Director | Buy | +1,000 | +$10.12K |
| 2021-11-18 | Richard A Barasch | Director | MIXED | +85,113 | — |
| 2021-11-18 | Brad Hively | Chief Executive Officer | A | +353,450 | — |
| 2021-11-16 | Richard A Barasch | Director | MIXED | +85,113 | — |
| 2021-11-16 | Daniel Virnich | Chief Operating Officer | A | +195,236 | — |
| 2021-11-16 | Brad Hively | Chief Executive Officer | A | +353,450 | — |
| 2021-11-16 | Scott Dalgleish | Chief Financial Officer | A | +118,916 | — |
| 2021-11-16 | Yale Podnos | Chief Medical Officer | A | +28,398 | — |
| 2021-11-16 | Ravi Yang Sarin | Director | A | +4,109,771 | — |
| 2021-11-16 | Mohit Kaushal | Director | MIXED | +25,534 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jorey Chernett | 10%+ Owner | 10,660,858 | $54.69M |
| Brad Hively | Chief Executive Officer | 411,976 | $2.11M |
| Anne McGeorge | Director | 332,535 | $1.71M |
| Karen Marie Johnson | Director | 319,410 | $1.64M |
| Mark L Pacala | Director | 286,881 | $1.47M |
| Yale Podnos | Chief Medical Officer | 259,527 | $1.33M |
| Mohit Kaushal | Director | 205,716 | $1.06M |
| Mark Stolper | Director | 56,957 | $292.19K |
| Kimberly Jo Tzoumakas | Director | 46,301 | $237.52K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TOI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.